Alex Zhavoronkov
PulseAugur coverage of Alex Zhavoronkov — every cluster mentioning Alex Zhavoronkov across labs, papers, and developer communities, ranked by signal.
1 day(s) with sentiment data
-
US patent law struggles to credit AI inventors in drug discovery
Intellectual property law currently faces a significant challenge as artificial intelligence systems are increasingly capable of generating novel drug designs. Despite AI's role in these discoveries, current patent laws…
-
Generative biology uses AI to design drugs now in human trials
Generative biology, which uses AI to design molecules and biological functions, is transitioning from research to clinical application. Companies like Generate Biomedicines and Insilico Medicine are leveraging AI to cre…
-
AI accelerates drug discovery, but data quality and lab bottlenecks remain challenges · 4 sources tracked
Artificial intelligence is accelerating drug discovery by enabling predictive design of drug candidates, which reduces the need for extensive physical screening. However, this speed highlights bottlenecks in laboratory …
-
Takeda partners with Insilico Medicine for $600M AI drug discovery deal
Takeda Pharmaceutical Company has entered into a strategic collaboration with Insilico Medicine, utilizing AI for early-stage drug discovery. The deal, potentially worth up to US$600 million, grants Takeda exclusive wor…
-
Insilico Medicine and SK Biopharmaceuticals ink $2.5B AI drug discovery deal
Insilico Medicine and SK Biopharmaceuticals have entered into a significant research collaboration valued at over $2.5 billion. The partnership will leverage Insilico's AI-driven Pharma.AI platform to discover novel dru…
-
Insilico and Human Longevity partner on AI disease prediction models
Insilico Medicine and Human Longevity have formed a partnership to develop AI foundation models aimed at predicting diseases decades in advance. This collaboration combines Insilico's AI algorithms with Human Longevity'…